Galectin 9 is expressed by tumor cells and is a ligand of dectin 1, whereby the galectin 9/dectin 1 axis induces the polarization of macrophages toward an M2 phenotype [148]; therefore, the silencing of galectin 9 suppresses the generation of protumoral macrophages, and the combination with oxaliplatin induces immunogenic death, enhancing the immune response. Here, CLEC7A is linked to neoplasm.